Toggle

A modified virus (VSV-hIFNbeta-NIS), alone or with other drugs, to treat acute myeloid leukemia (AML), multiple myeloma, myelodysplastic syndrome (MDS) or T-cell lymphoma that has come back (relapsed) or has not gotten better with treatment (refractory) 

Print

18 and older

Phase 1

2 Locations

NCT03017820

Clinical Trial Goal


To find out if VSV-hIFNbeta-NIS, alone or with other drugs, is safe and works well to treat AML, multiple myeloma, or T-cell lymphoma that has relapsed or is refractory 

You may be able to join this trial if you:


  • Are 18 years old or older
  • Have one of the following diseases that has relapsed or is refractory:
    • AML
    • Anaplastic large cell lymphoma (ALCL)
    • Angioimmunoblastic T-cell lymphoma (AITL)
    • B-cell non-Hodgkin lymphoma (NHL)
    • Cutaneous T-cell lymphoma (CTCL)
    • MDS
    • Multiple myeloma
    • Mycosis fungoides
    • Peripheral T-cell lymphoma (PTCL) 
  • Do not have acute promylelocytic leukemia
  • Do not have cancer in your brain or spinal cord
  • Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) 
  • Agree to have other standard tests done to see if you can be in the clinical trial

Trial Details


Cemiplimab is a monoclonal antibody that target PD-1  on certain cells.
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells.
Ipilimumab is a checkpoint inhibitor that targets CTLA-4 on certain cells.
VSV-hIFNbeta-NIS is a virus that has been treated in a lab. Doctors think this virus can find and kill cancer cells.

In this trial, you’ll be placed in 1 of 4 groups based on your diagnosis and what the clinical trial doctors thinks is best for your health. You'll be told what group you're in:
  • Group 1 – VSV-hIFNbeta-NIS
  • Group 2 - VSV-hIFNbeta-NIS plus ipilimumab and cemiplimab
  • Group 3 - VSV-hIFNbeta-NIS plus ruxolitinib, ipilimumab and cemiplimab


You’ll get:
  • Cemiplimab - Group 2 and 3 only - Given as an intravenous (IV) infusion 1 time
  • Ipilimumab - Group 2 and 3 only - Given as an IV infusion 1 time
  • VSV-hIFNbeta-NIS – Given as an IV infusion 1 time. The infusion takes about 30 minutes

You'll have scans to see how well the treatment is working. After you finish treatment, the clinical trial doctors will check your health for up to 2 years.

The Food and Drug Administration (FDA) has not yet approved VSV-hIFNbeta-NIS. All of the other drugs used have been approved. 

Contacts


Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu

Locations


Mayo Clinic in ArizonaRECRUITING

Scottsdale, Arizona
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu

Mayo Clinic in RochesterRECRUITING

Rochester, Minnesota
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu

ClinicalTrials.gov record


NCT03017820. First posted on 1/11/17

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org